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Abstract
Purpose To determine whether
intraocular pressure (IOP) lowering with
fixed-combination brinzolamide/brimonidine
(BBFC) adjunctive to a prostaglandin analog
(PGA) was superior to that of vehicle+PGA
in patients with open-angle glaucoma or
ocular hypertension who were inadequately
controlled with PGA monotherapy
Methods This 6-week, multicenter,
randomized, double-masked, parallel-group
trial was conducted at 30 clinical sites in the
United States between October 2013 and
May 2014. Eligible patients were adults with
open-angle glaucoma or ocular hypertension
and with mean IOP ≥ 21 and o32 mmHg,
whereas receiving an open-label PGA
(latanoprost, bimatoprost, or travoprost).
Patients instilled a PGA once-daily in a run-in
phase before randomization to masked BBFC
or vehicle adjunctive treatment. Masked
treatments were instilled 3 times daily for
6 weeks, and patients continued once-daily
use of their PGA. The primary efficacy end
point was the between-group difference in
mean diurnal IOP (average of 0800, 1000,
1500, and 1700 hours time points) at week 6.
Results At week 6, mean diurnal IOP with
BBFC+PGA was lower than with vehicle
+PGA (17.1± 0.4 mmHg vs 20.5± 0.4 mmHg;
between-group difference, − 3.4± 0.5 mmHg;
Po0.0001; 95% confidence interval, − 4.5 to
− 2.4 mmHg). BBFC+PGA reduced mean
diurnal IOP by 5.7 mmHg (25%) from the
baseline IOP achieved with PGA
monotherapy.
Conclusions Therapy with BBFC produced
an additive IOP-lowering effect compared
with a PGA alone or in conjunction with
vehicle. BBFC may provide an effective
treatment option for patients receiving PGA
monotherapy who require additional IOP
reduction.
Eye (2016) 30, 1343–1350; doi:10.1038/eye.2016.126;
published online 1 July 2016
Introduction
Insufficient intraocular pressure (IOP) control is a
primary risk factor for progression of ocular
hypertension and glaucoma,1 and elevated IOP is
associated with increased risk for vision loss.2
Prostaglandin analogs (PGAs) are highly effective
first-line therapies for lowering IOP.3 As many as
50% of patients in the Ocular Hypertension
Treatment Study required additional ocular
hypotensive medications to maintain IOP reduction
after the first year of treatment.4 Although the
safety and efficacy of adding a fixed-combination
medication containing timolol to prostaglandin
monotherapy have been demonstrated,5–7 data are
needed to evaluate the addition of a fixed
combination without a β-blocker to PGAs.
Brinzolamide 1%/brimonidine 0.2% fixed-
combination ophthalmic suspension (BBFC;
SIMBRINZA, Alcon Laboratories, Fort Worth,
TX, USA) is currently the only fixed-combination
glaucoma therapy that does not contain a
β-blocker.8 In randomized, double-masked
trials, treatment with BBFC 2 times daily (BID;
approved dosing in most countries) or 3 times
daily (approved dosing in the United States)
significantly reduced IOP by ~ 20–35% from
baseline, and BBFC was more effective than
either of its components.9–13
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The objective of this study was to determine whether
IOP lowering with BBFC adjunctive to PGA (BBFC+PGA)
was superior to that of vehicle+PGA in patients with
open-angle glaucoma or ocular hypertension who were
inadequately controlled with PGA monotherapy.
Patients and methods
Study design, treatment, and randomization
This 6-week, randomized, parallel-group trial was conducted
at 30 sites in the United States between October 2013 and
May 2014 (ClinicalTrials.gov ID, NCT01937312). The study
included 5 visits conducted in 2 phases: phase 1 was an
open-label run-in phase in which patients received an
investigator-assigned PGA, and phase 2 was a double-
masked treatment phase in which patients were randomized
to receive BBFC or vehicle in addition to the PGA used
during phase 1.
The open-label phase consisted of a screening visit
and 2 eligibility visits conducted 3–8 days apart, with
the first eligibility visit conducted up to 28± 3 days
after screening based on the washout schedule of prior
medications. At screening, patients discontinued other
IOP-lowering medications and were assigned by study
investigators a branded PGA: XALATAN (latanoprost
0.005%; Pfizer, New York, NY, USA), LUMIGAN
(bimatoprost 0.01%; Allergan, Irvine, CA, USA), or
TRAVATAN Z (travoprost 0.004%; Alcon Laboratories)
to be taken once-daily at bedtime for the duration of
the study. A ratio of ~ 2 : 2 : 1 was achieved by imposing
ceilings on the total numbers of patients receiving
each investigator-assigned PGA. Patients who met all
inclusion/exclusion criteria at both eligibility visits were
randomized to masked BBFC or vehicle 3 times daily at
~ 0800, 1500, and 2200 hours for 6 weeks in addition to
their once-daily PGA. On-therapy follow-up visits were
scheduled after 2 weeks± 3 days and 6 weeks± 5 days
of treatment with BBFC+PGA or vehicle+PGA.
For the randomized, double-masked treatment phase of
the study, eligible patients were sequentially randomized
by designated personnel at each study site to BBFC or
vehicle using a schedule provided by the study sponsor.
The series of randomization numbers were generated using
PROC PLAN in SAS 9.1 (SAS Institute, Cary, NC, USA)
to generate 100 balanced blocks of size 4 in a 1 : 1 ratio.
Blocks were allocated on demand using an electronic-data-
collection system with interactive response technology
web software and stratified by investigator and patients’
study PGA to ensure a balance of treatment allocations
within study sites and type of PGA.
To minimize potential selection bias, patients,
investigators, study site personnel, the study sponsor, and
clinical monitors were masked to treatment assignments.
Multiple study sites were used to eliminate the potential
of single-observer bias. Personnel administering study
medications during on-therapy visits did not discuss
treatments or participate in IOP measurements, and study
investigators were not allowed to administer treatments
during the study. BBFC and vehicle were provided to
study investigators using identical masked bottles, labels,
and packaging with the kit number indicated, and the
randomization schedule was restricted until after the
database was locked and the study was unmasked.
The study was performed in accordance with Good
Clinical Practice and the Declaration of Helsinki, and
participating patients provided informed consent. The
study protocol and consent documents were approved
by Western Institutional Review Board (Olympia, WA,
USA), Wills Eye Hospital Institutional Review Board
(Philadelphia, PA, USA), Summa Health System
Institutional Review Board (Akron, OH, USA), and
Sterling Institutional Review Board (Atlanta, GA, USA)
before the start of the study.
Patients
Patients were enrolled by individual study investigators.
Eligible patients were aged ≥ 18 years, diagnosed with
open-angle glaucoma (including pseudoexfoliation or
pigment dispersion) or ocular hypertension, and had a
mean IOP of ≥ 21 and o32 mmHg in at least 1 eye at
0800 hours during both eligibility visits, whereas on PGA
monotherapy. Patients with IOP ≥ 32 mmHg in either eye
at any time point were excluded.
Additional key exclusion criteria were central corneal
thickness 4620 μm, Shaffer angle grade o2, cup-to-disc
ratio 40.8, or severe central visual field loss in either eye;
chronic recurrent or severe inflammatory eye disease;
clinically significant or progressive retinal disease; ocular
surgery or trauma ≤6 months before screening; ocular laser
surgery, infection, or inflammation ≤3 months before
screening; best-corrected visual acuity worse than 55 Early
Treatment Diabetic Retinopathy Study letters (equivalent
to 20/80 Snellen or 0.6 logMAR) in both eyes; and use of
additional ocular hypotensive medications during the study.
End points
The primary efficacy end point was the between-group
difference in mean diurnal IOP (average of 0800, 1000,
1500, and 1700 hours measurements) at week 6.
Secondary efficacy end points were mean IOP at each
time point at week 6, mean diurnal IOP change from
baseline at week 6, and percent diurnal IOP change from
baseline at week 6. Mean diurnal IOP, mean and percent
diurnal IOP change from baseline, and IOP at individual
time points at week 2; and mean and percent IOP change
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from baseline at individual time points at weeks 2 and 6
were also assessed. Mean IOP at each time point at week 6
was considered a supportive end point in the protocol,
but was elevated to a secondary end point before
completion of the study. This change was noted in the
statistical analysis plan before study completion.
IOP was measured by an operator and a reader using
Goldmann applanation tonometry. Two measurements
were taken for each eye. If measurements differed by
≤ 4 mmHg, the average value was considered the mean
IOP for that eye. If measurements differed by44 mmHg,
a third measurement was taken and the two closest
values were averaged. If the three measurements differed
by equal amounts, all three measurements were aver-
aged. IOP was measured at screening and at 0800 hours
(±30 min), 1000 hours (±30 min), 1500 hours (±30 min),
and 1700 hours (±30 min) during the two eligibility
visits and at the week 2 and week 6 follow-up visits.
Safety evaluations included adverse event (AE) reports,
automated perimetry, dilated-eye examination, best-corrected
visual acuity, and slit-lamp biomicroscopy. Best-corrected
visual acuity and biomicroscopy assessments were
performed at the screening, eligibility, and on-therapy follow-
up visits. Perimetry and dilated fundus examination were
performed at screening and at the week 6 follow-up visit.
Statistical analyses
Efficacy end points were analyzed in the intent-to-treat
data set (all patients who received study medication
and completed at least 1 scheduled on-therapy visit).
The safety data set included all patients who received
study medication.
Data for one eye per patient were used for efficacy
analyses. If both eyes were treated, the eye with higher
IOP at 0800 hours averaged across both eligibility visits
was selected as the study eye. If both eyes had equal IOP
at 0800 hours, the eye with higher IOP at 1000 hours was
selected. If both eyes had equal IOP at 0800 hours and
1000 hours, the right eye was selected as the study eye. The
primary and secondary efficacy end points were analyzed
on an observed-case basis using a statistical analysis model
that was robust for data that were missing at random.
The superiority of BBFC+PGA relative to vehicle+PGA
was established if the mean diurnal IOP at week 6 was
significantly lower in the BBFC+PGA group vs the vehicle
+PGA group. Treatment group differences for the primary
and secondary efficacy end points were determined
using tests based on the least squares means derived
from a repeated measures statistical model that accounted
for correlated IOP measurements within a patient.
A sequential testing approach was used to account for
multiplicity of analyses. Patient demographics, including
race and baseline characteristics, supportive efficacy end
points, and safety data were summarized descriptively.
Information regarding race was collected to enable
potential post hoc analysis of study outcomes by race
categories; patients self-identified their race at screening,
and no race categories were predefined. All statistical
analyses were performed using SAS software (SAS
Institute) with Po0.05 considered statistically significant.
Assuming a common standard deviation ranging from
3.5 to 3.9 mmHg for mean IOP and an estimated drop-out
rate of 20%, ~ 200 patients were required to provide
≥ 90% power to detect a between-group difference in
mean diurnal IOP of 2.0 mmHg using a two-sample,
two-sided t-test at a significance level of αo0.05.
Trial registration
This study is registered at ClinicalTrials.gov; ID
NCT01937312 (https://clinicaltrials.gov).
Results
Patients
Of the 282 patients assessed for eligibility, 188 were
randomized and received study medication; these patients
comprised the safety data set. There were 93 screening
failures; most (62.4%) were because patients did not meet
IOP criteria at enrollment. The intent-to-treat data set
included 182 patients (BBFC+PGA, n= 88; vehicle+PGA,
n= 94; Supplementary Figure S1). One patient randomized
to BBFC+PGA did not receive study medication and
was excluded from the intent-to-treat and safety analyses.
Most patients completed the study (92.6%, n= 175/189;
Supplementary Figure S1); 11 patients receiving BBFC
+PGA and 3 patients receiving vehicle+PGA discontinued.
AEs were the most common reason for discontinuation
(5.8% overall, n= 11/189). Discontinuations because of an
AE were reported for 10.6 and 1.1% of patients in the BBFC
+PGA group and the vehicle+PGA group, respectively.
Most patients in the intent-to-treat data set were female
(63.7%), white (63.7%), and diagnosed with open-angle
glaucoma (78.6%; Table 1). The PGA allocation was similar
between groups. Mean diurnal IOP at PGA-treated baseline
was 22.7± 2.1 mmHg and 22.4± 2.8 mmHg in the BBFC
+PGA group and the vehicle+PGA group, respectively.
Efficacy
Mean diurnal IOP at week 6 was significantly lower
in patients receiving BBFC+PGA compared with
patients receiving vehicle+PGA (Figure 1). Least squares
mean± SE diurnal IOP was 17.1± 0.4 mmHg with BBFC
+PGA (95% CI, 16.3–17.8 mmHg) vs 20.5± 0.4 mmHg
with vehicle+PGA (95% CI, 19.8–21.2 mmHg). The between-
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group difference was −3.4±0.5 mmHg (Po0.0001; 95% CI,
−4.5 to −2.4mmHg); therefore, the criterion for superiority
of BBFC+PGA was met. Mean IOP at week 6 was
significantly lower at all time points with BBFC+PGA
compared with vehicle+PGA (Figure 2; P≤ 0.0002).
Least squares mean±SE between-group differences ranged
from −2.1±0.6 to −4.6±0.6 mmHg, with the maximum
difference observed at 1000 hours (ie, peak efficacy). Mean
diurnal IOP change from PGA-treated baseline was
significantly greater with BBFC+PGA (−5.7± 0.3 mmHg)
compared with vehicle+PGA (−1.9±0.3 mmHg). The
between-group difference was −3.7±0.4 mmHg
(Po0.0001; 95% CI, −4.5 to −2.9 mmHg; Figure 3a).
The percent diurnal IOP change from baseline was also
significantly greater in the BBFC+PGA group (−24.7±1.3%)
compared with the vehicle+PGA group (−8.2±1.2%;
between-group difference, −16.5±1.8%; Po0.0001; 95% CI,
−20.0% to −13.0%; Figure 3b). Mean IOP change from
baseline at each week 6 time point was numerically greater
with BBFC+PGA compared with vehicle+PGA (Figure 3c).
At the week 6, 1000 hours time point (peak efficacy), the
mean±SE IOP change from baseline was −7.1± 0.4 mm
Hg (−30.9±1.7%) with BBFC+PGA and −2.4± 0.3 mmHg
(−10.6±1.5%) with vehicle+PGA. Mean IOP, mean IOP
change from baseline, and mean percent IOP change from
baseline for diurnal IOP and IOP at individual time points at
weeks 2 and 6 are presented in Table 2.
Safety
The mean± SE duration of exposure to study medication
was 39.6± 1.1 days and 41.2± 0.6 days in the BBFC+PGA
Table 1 Patient demographics and baseline characteristicsa,b
BBFC+PGA
(n= 88)
Vehicle+PGA
(n= 94)
Age, years
Mean± SD 65.5± 9.4 64.7± 9.6
Range 36–86 30–87
Sex, n (%)
Female 53 (60.2) 63 (67.0)
Male 35 (39.8) 31 (33.0)
Race, n (%)
White 61 (69.3) 55 (58.5)
Black or African American 25 (28.4) 39 (41.5)
Asian 2 (2.3) 0
Diagnosis, n (%)
Open-angle glaucoma 72 (81.8) 71 (75.5)
Ocular hypertension 15 (17.0) 19 (20.2)
Open-angle glaucoma with
pseudoexfoliation
0 1 (1.1)
Open-angle glaucoma with
pigment dispersion
1 (1.1) 3 (3.2)
PGA monotherapy, n (%)
Latanoprost 0.005% 33 (37.5) 37 (39.4)
Bimatoprost 0.01% 31 (35.2) 33 (35.1)
Travoprost 0.004% 24 (27.3) 24 (25.5)
Diurnal intraocular pressure, mm Hg
Mean± SD 22.7± 2.1 22.4± 2.8
Range 18.0–27.8 16.0–30.5
Abbreviations: BBFC, fixed-combination brinzolamide 1%/brimonidine
0.2%; PGA, prostaglandin analog; SD, standard deviation. a Percentages
may not add up to 100 because of rounding off. bNo meaningful differences
were observed between treatment groups for any demographic characteristic.
Figure 1 Mean diurnal IOP at week 6. Data are presented as
least squares mean and standard error. Between-group difference
is depicted above bars. *Po0.0001.
Figure 2 Mean IOP at week 6 time points. Data are presented as
least squares mean and standard error. Mean IOP is indicated
inside bars; between-group differences are indicated above bars.
*P= 0.0002; †Po0.0001.
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and vehicle+PGA groups, respectively. AEs were reported
for 35.5 and 21.1% of patients who received BBFC+PGA
and vehicle+PGA, respectively (Supplementary Table S1).
One patient receiving BBFC+PGA experienced two non-
fatal serious AEs (hypoglycemia and metastatic malignant
melanoma) unrelated to study treatment. Blurred vision
was the most frequently reported AE in both groups
and was considered treatment-related in all cases
(BBFC+PGA, 9.7%; vehicle+PGA, 6.3%). Other common
AEs included eye irritation, eye pruritus, and ocular
hyperemia; these were reported at higher incidences in
the BBFC+PGA group compared with the vehicle+PGA
group (Supplementary Table S1). Two severe treatment-
related events (pruritus and ocular hyperemia) were
reported for the BBFC+PGA group. No serious treatment-
related AEs were reported for either group.
Ten patients in the BBFC+PGA group discontinued
the study, because of the following treatment-related AEs:
allergic conjunctivitis, conjunctival follicles, conjunctivitis,
eyelid edema, eye discharge, eye irritation, eye pain,
foreign body sensation, increased lacrimation,
iridocyclitis, ocular hyperemia, photophobia, pruritus,
and blurred vision. One patient receiving vehicle+PGA
discontinued because of concussion, joint injury, and
skeletal injury. No patients receiving BBFC+PGA and 1
patient receiving vehicle+PGA discontinued the study
because of insufficient IOP control.
Minimal changes in visual acuity (o3 letters)
were observed in both treatment groups. Ocular signs
were generally unchanged from baseline; alterations in
conjunctiva and eyelids were more common in patients
receiving BBFC+PGA compared with vehicle+PGA
(conjunctiva, 12.9 vs 4.3%; eyelids, 3.2 vs 2.1%). Corneal
alterations were observed in 3.2% of patients receiving
vehicle+PGA and 0% of patients receiving BBFC+PGA.
No changes in visual fields or meaningful between-group
differences in fundus parameters were observed.
Figure 3 Mean IOP change and percent IOP change from baseline to week 6. (a) Mean diurnal IOP change from baseline; (b) mean
percent diurnal IOP change from baseline; and (c) mean IOP change (mean percent change) from baseline by time point. Least squares
means and standard error are plotted for diurnal IOP change; descriptive means and standard error are plotted for IOP change at
individual time points. Means are indicated within bars; between-group differences are depicted below bars. *Po0.0001.
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Discussion
IOP reduction for patients with ocular hypertension or open-
angle glaucoma decreases the risk of progressive optic nerve
damage and visual field defects. Despite the known efficacy
of PGAs, a large retrospective cohort analysis demonstrated
that ~12–23% of patients receiving initial monotherapy
with bimatoprost, latanoprost, or travoprost required an
adjunctive therapy.14 Therefore, this study sought to
determine whether there would be additional IOP-lowering
efficacy if BBFC were added to a PGA in patients not
sufficiently controlled with PGA treatment alone.
The IOP-lowering efficacy of BBFC+PGA has not
been assessed previously. Our results demonstrated that
three-times-daily BBFC produced clinically meaningful IOP
reductions when added to a PGA; these reductions were
significantly greater than those achieved with vehicle
+PGA. A reduction in IOP (diurnal IOP: 1.9 mmHg, 8%;
peak reduction: 2.4 mmHg, 11%) was observed in the
vehicle+PGA group, similar to previous observations.15
A meta-analysis of clinical trials that assessed common
ocular hypotensive agents estimated that vehicle treatment
results in small but measurable decreases in IOP ranging
from 1.3 mmHg (5%) at trough to 1.6 mmHg (5%) at
peak.15 This effect may reflect regression to the mean or
improved compliance with active medication(s) when
placebo is added because of participation in a clinical trial;
however, consistent observations of IOP reduction with
placebo alone suggest that 1 or more components of vehicle
formulations may provide a small degree of IOP reduction.
The IOP reductions produced with BBFC+PGA in this
study were significantly greater than those reported for
brinzolamide+PGA or brimonidine+PGA. A randomized,
parallel-group study of PGA-treated patients demonstrated
that addition of three-times-daily brimonidine 0.15% or
brinzolamide 1% produced IOP reductions from PGA-
treated baseline of 4.8 mmHg (21%) and 3.4 mmHg (16%),
respectively, at 1000 hours (peak effect) after 4 months
of adjunctive therapy. In the current study, peak IOP
reduction from baseline with BBFC+PGA was 7.1 mmHg
(31%), indicating that adding BBFC to a PGA is more
effective than adding brimonidine or brinzolamide
individually. This finding is consistent with demonstrations
of significantly greater IOP-lowering efficacy of BBFC
compared with either component alone.11–13
The effectiveness of treating glaucoma with a fixed
combination and a single-agent therapy has been
shown previously. After 6 weeks of treatment with fixed-
combination brimonidine/timolol added to latanoprost,
mean IOP at 1000 hours (peak IOP-lowering efficacy) was
reduced by 36% from latanoprost-treated baseline levels
of 23.0 mmHg to 23.4 mmHg.5 This report is not directly
comparable to the current study because mean diurnal
IOP reductions were not described; however, the 36% IOP
reduction at peak was similar to the 31% reduction at the
week 6, 1000 hours peak efficacy time point described here.
Adding brinzolamide to fixed-combination travoprost/
timolol reduced mean diurnal IOP by 14% from the
travoprost/timolol-treated baseline of 20.3 mmHg after
12 weeks.16 Further, fixed-combination brinzolamide/
timolol or brimonidine/timolol added to travoprost
reduced IOP from travoprost-treated baseline (20.1 mmHg)
by 14 and 10%, respectively, after 3 months.6 In the current
study, BBFC+PGA produced a mean diurnal IOP reduction
Table 2 Descriptive statistics for IOP by visit and time point
BBFC+PGA Vehicle+PGA
Mean± SE IOP, mm Hg Mean± SE IOP, mm Hg
n IOP IOP change
from baseline
Percent IOP change
from baseline
n IOP IOP change
from baseline
Percent IOP change
from baseline
Baseline
0800 hours 88 24.5± 0.3 — — 94 24.3± 0.3 — —
1000 hours 88 22.9± 0.2 — — 94 22.6± 0.3 — —
1500 hours 88 21.7± 0.3 — — 94 21.3± 0.3 — —
1700 hours 88 21.6± 0.3 — — 94 21.2± 0.4 — —
Mean diurnal 88 22.7± 0.2 — — 94 22.4± 0.3 — —
Week 2
0800 hours 88 18.8± 0.4 − 5.6± 0.4 − 22.8± 1.6 94 21.8± 0.4 − 2.5± 0.3 − 10.3± 1.3
1000 hours 86 15.7± 0.4 − 7.2± 0.4 − 31.5± 1.6 93 20.2± 0.4 − 2.4± 0.3 − 10.5± 1.3
1500 hours 86 16.9± 0.3 − 4.8± 0.3 − 21.8± 1.4 93 19.9± 0.4 − 1.5± 0.4 − 6.1± 1.6
1700 hours 86 15.3± 0.4 − 6.3± 0.4 − 28.8± 1.5 92 19.4± 0.4 − 1.8± 0.3 − 7.5± 1.7
Mean diurnal 88 16.8± 0.3 − 6.0± 0.3 − 26.0± 1.3 94 20.4± 0.4 − 2.0± 0.3 − 8.5± 1.2
Week 6
0800 hours 83 19.4± 0.4 − 5.1± 0.4 − 20.6± 1.5 92 21.4± 0.5 − 2.9± 0.4 − 12.0± 1.4
1000 hours 83 15.8± 0.4 − 7.1± 0.4 − 30.9± 1.7 92 20.2± 0.4 − 2.4± 0.3 − 10.6± 1.5
1500 hours 83 17.2± 0.3 − 4.5± 0.3 − 20.6± 1.4 92 19.9± 0.4 − 1.4± 0.4 − 6.1± 1.6
1700 hours 83 15.6± 0.3 − 5.9± 0.3 − 27.4± 1.4 92 19.9± 0.5 − 1.2± 0.4 − 5.3± 1.6
Mean diurnal 83 17.0± 0.3 − 5.7± 0.3 − 24.9± 1.2 92 20.4± 0.4 − 2.0± 0.3 − 8.5±1.3
Abbreviations: BBFC, fixed-combination brinzolamide 1%/brimonidine 0.2%; IOP, intraocular pressure; PGA, prostaglandin analog; SE, standard error.
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of 25% at week 6 (compared with 8% in the vehicle+PGA
group), suggesting that BBFC added to a PGAmay produce
IOP reductions similar to those observed in prior studies of
a three-agent treatment regimen that included a β-blocker.
Previous studies suggest that the magnitudes of IOP
reductions achieved with BBFC+PGA in the current
study were clinically relevant and may reduce patients’
risk of disease progression with long-term use. For
example, results of the Early Manifest Glaucoma
Trial (EMGT) demonstrated that the risk of progression
decreased by 10% with each 1 mmHg decrease in mean
IOP.17 In the current study, the mean IOP decrease from
baseline in the BBFC+PGA group was ≥ 4.5 mmHg
at weeks 2 and 6 at all time points assessed. Further,
a meta-analysis of 4 studies including a total of 822
patients identified mean IOP as a significant risk
factor for progression.1 Progression over 5 years of
follow-up was reported for more than half of patients
with mean IOP420 mmHg compared with ≤ 18% of
patients with mean IOP of between 13 and 17 mm Hg.1
In the current study, mean diurnal IOP was decreased
from 22.7 mmHg at baseline to ~ 17 mmHg at
weeks 2 and 6; with the exception of the trough efficacy
time point at 0800 hours (19.4 mmHg), mean IOP at
individual time points at weeks 2 and 6 was generally
≤ 17 mm Hg.
As expected, AEs were more common in patients
receiving BBFC+PGA, likely because the BBFC+PGA
group was exposed to three active medications
compared with only one in the vehicle+PGA group.
Furthermore, treatment intolerance or PGA-related AEs
likely occurred during the open-label run-in phase of
the study. Most treatment-related AEs in the BBFC
+PGA group were consistent with the known safety
profiles of BBFC, brinzolamide, brimonidine, and
PGAs.8,18 No new safety concerns were identified
regarding addition of BBFC to a PGA.
A potential limitation of this study was that it did not
evaluate the degree to which PGA treatment contributed
to IOP control. In addition, because efficacy was evaluated
in the eye with higher baseline IOP for all patients (ie, the
‘worse’ eye), the absolute magnitudes of IOP reduction
observed in the BBFC+PGA and vehicle+PGA groups may
be greater than would be observed in a clinical setting
(ie, for a patient’s ‘better’ eye). However, this approach
is frequently taken in glaucoma studies to ensure patient
safety by monitoring efficacy in the eye at greater risk of
glaucoma-related complications and parallels physicians’
concerns about managing the more severe manifestation
of a patient’s glaucoma or ocular hypertension. Because
both treatment groups were analyzed using this approach,
no treatment bias was introduced.
In conclusion, adding BBFC to PGA therapy produced
a mean diurnal IOP reduction of 5.7 mmHg (25%)
compared with PGA-treated baseline and was superior
to vehicle+PGA. BBFC+PGA therapy was well-tolerated,
and no safety concerns were observed beyond the known
safety profiles of the individual agents. PGAs are often
preferred as initial monotherapy because of their IOP-
lowering efficacy, lower frequency of instillation, and
acceptable tolerability profiles. Adjunctive therapy with
BBFC can provide an effective option for patients requiring
additional IOP reduction beyond that achieved with PGA
monotherapy, particularly for patients who cannot tolerate
treatment with a β-blocker. Future studies incorporating
longer treatment durations and comparisons with other
fixed-combination medications will provide additional
valuable information describing the efficacy of BBFC+PGA
adjunctive therapy.
Summary
What was known before
K Many patients with glaucoma or ocular hypertension
require multiple medications to achieve and maintain
sufficient intraocular pressure (IOP) reduction.
K Prostaglandin analogs (PGAs) are first-line IOP-lowering
medications, and fixed-combination brinzolamide/
brimonidine (BBFC) is currently the only fixed-
combination IOP-lowering therapy that does not contain
a β-blocker.
What this study adds
K This study evaluated the additive IOP-lowering effect
of BBFC or vehicle adjunctive to a PGA (latanoprost,
bimatoprost, or travoprost) used at baseline and continued
for 6 weeks.
K BBFC+PGA was well-tolerated and the IOP-lowering
efficacy of BBFC+PGA was superior to vehicle+PGA.
After 6 weeks of treatment, BBFC+PGA reduced mean
diurnal IOP by 5.7 mm Hg (25%) from the baseline IOP
achieved with PGA monotherapy; at 2 h post-instillation,
BBFC+PGA reduced mean IOP by 7.1 mm Hg (31%) from
PGA-treated baseline.
K Adjunctive therapy with BBFC can provide an effective
option for patients requiring additional IOP reduction
beyond that achieved with PGA monotherapy.
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